Ihsan Fadilah_22010110120066_Bab8KTI

50 !

!

DAFTAR PUSTAKA

1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third

universal definition of myocardial infarction. Circulation [Internet]. 2012 [cited

2014 Feb 17]; 126:2012-35. Available from:

http://circ.ahajournals.org/content/126/16/2020.full.pdf+html

2. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mahonen M, Blackett KN, et

al. World Health Organization definition of myocardial infarction: 2008-09

revision. International Journal of Epidemiology [Internet]. 2011 [cited 2014 Feb

17]; 40:139-46. Available from:

http://ije.oxfordjournals.org/content/40/1/139.full.pdf+html

3. Global status report on noncommunicable diseases 2010. Geneva (Switzerland):

World Health Organization; 2011 [cited 2014 Feb 17]. Available from:

http://www.who.int/nmh/publications/ncd_report_full_en.pdf

4. Rosamod WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, et

al. Trends in the incidence of myocardial infarction and in mortality due to

coronary heart disease, 1987 to 1994. N Engl J Med [Internet]. 1998 [cited 2014

Feb 17]; 339:861-7. Available from:

http://www.nejm.org/doi/full/10.1056/NEJM199809243391301

5. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in

coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the

Framingham Heart Study. Circulation [Internet]. 2004 [cited 2013 Feb 17];

110:522-7. Available from: http://circ.ahajournals.org/content/110/5/522.full

6. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart

disease and stroke statistics–2007 update: a report from the American Heart

Association Statistics Commitee and Stroke Statistics Subcommitee. Circulation

[Internet]. 2007 [cited 2014 Feb 17]; 115:e69-171. Available from:

http://circ.ahajournals.org/content/115/5/e69.full

7. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left

ventricular systolic dysfunction after acute myocardial infarction: prevalence,

51 !

! !

51

clinical characteristics, and prognostic importance. Am J Cardiol [Internet]. 2006

[cited 2014 Feb 17]; 97:13F-25F. Available from:

http://www.ncbi.nlm.nih.gov/pubmed/16698331

8. Hellerman JP, Jacobsen SJ, Redfield MM, Reeder GS, Weston SA, Roger VL.

Heart failure after myocardial infarction: clinical presentation and survival. The

European Journal of Heart Failure [Internet]. 2005 [cited 2014 Feb 17]; 7:119-25.

Available from: http://eurjhf.oxfordjournals.org/content/7/1/119.full.pdf+html

9. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–Concepts and clinical

implications: a consensus paper from an international forum on cardiac

remodeling. J Am Coll Cardiol [Internet]. 2000 [cited 2014 Feb 17]; 35(3):569-

82.

10. Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial infarction:

pathophysiology and therapy. Circulation [Internet]. 2000 [cited 2014 Feb 17];

101:2981-8. Available from: https://circ.ahajournals.org/content/101/25/2981.full

11. Rame JE, Dries DL. Heart failure and cardiac hypertrophy. Current Treament

Options in Cardiovascular Medicine [Internet]. 2007 [cited 2014 Feb 18];

9(4):289-301. Available from:

http://link.springer.com/article/10.1007%2Fs11936-007-0024-3

12. Ishii H, Amano T, Matsubara T, Murohara T. Pharmacological intervention for

prevention of left ventricular remodeling and improving prognosis in myocardial

infarction. Circulation [Internet]. 2008 [cited 2014 Feb 22]; 118:2710-18.

Available from: https://circ.ahajournals.org/content/118/25/2710.full.pdf+html

13. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, et

al. Long-term trends in the incidence of heart failure after myocardial infarction.

Circulation [Internet]. 2008 [cited 2014 Feb 22]; 118(20):2057-62. Available

from: http://www.ncbi.nlm.nih.gov/pubmed/18955667

14. Cicero AFG, Tartagni E, Ertek S. Metformin and its clinical use: new insights for

an old drug in clinical practice. Arch Med Sci [Internet]. 2012 [cited 2014 Feb

18]; 8(5):907-17. Available from:


52 !

! !

52

15. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect

of metformin treatment on multiple cardiovascular disease risk factors in patients

with type 2 diabetes mellitus. Metabolism [Internet]. 2004 [cited 2014 Feb 18];

53(2):159-64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14767866

16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-

glucose control with metformin on complications in overweight patients with type

2 diabetes (UKPDS 34). Lancet [Internet]. 1998 [cited 2014 Feb 18];

352(9139):1558. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9742977

17. Holman RR, Paul SK, Bethel MA, Mattews DR, Neil HA. Ten year follow-up of

intensive glucose control in type 2 diabetes. N Engl J Med [Internet]. 2008 [cited

2014 Feb 14]; 359(15): 1577-89. Available from:


18. Chan AM, Soltys CM, Young ME, Proud CG, Dyck JR. Activation of AMP-

activated protein kinase inhibits protein synthesis associated with hypertrophy in

the cardiac myocyte. J Biol Chem [Internet]. 2004 [cited 2014 Feb 18];

279(31):32771-9. Available from:


19. Fu YN, Xiao H, Ma XW, Jiang SY, Xu M, Zhang YY. Metformin attenuates

pressure overload-induced cardiac hypertrophy via AMPK activation. Acta

Pharmacol Sin [Internet]. 2011 [cited 2014 Feb 18]; 32(7):879-87. Available


20. Cha HN, Choi JH, Kim YW, Kim JY, Ahn MW, Park SY. Metformin inhibits

isoproterenol-induced cardiac hypertrophy in mice. Korean J Physiol Pharmacol

[Internet]. 2010 [cited 2014 Feb 18]; 14(6):377-84. Available from:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034117

21. Wong AK, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway:

a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond)

[Internet]. 2009 [cited 2014 Feb 23]; 116(8):607-20. Available from:


22. Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive

therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc

53 !

! !

53

Res [Internet]. 2011 [cited 2014 Feb 23]; 90(2):224-33. Available from:


23. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Sillje HH, de Boer

RA. Metformin improves cardiac function in a nondiabetic rat model of post-MI

heart failure. Am J Physiol Heart Circ Physiol [Internet]. 2011 [cited 2014 Feb

18]; 301(2):H459-68. Available from:


24. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, et al. Activation

of AMP-activated protein kinase by metformin improves left ventricular function

and survival in heart failure. Circ Res [Internet]. 2009 [cited 2014 Feb 18];


25. Benes J, Kazdova L, Drahota Z, Houstek J, Medrikova D, Kopecky J, et al. Effect

of metformin therapy on cardiac function and survival in a volume-overload

model of heart failure in rats. Clin Sci (Lond) [Internet]. 2011 [cited 2014 Feb

21]; 121(1):29-41. Available from:


26. Naik H, Sabatine MS, Lilly LS. Ischemic heart disease. In: Lilly LS, editor.

Pathophysiology of heart disease : a collaborative project of medical students and

faculty. 4th ed. Baltimore/Philadelphia: Lippincott Williams & Wilkins; 2007. p.

141-69.

27. Gao E, Koch WJ. A novel and efficient model of coronary artery ligation in

mouse. Methods Mol Biol [Internet]. 2013[cited 2014 Feb 21]; 1037:299-311.

Available from: http://www.ncbi.nlm.nih.gov/pubmed/24029943

28. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Buocher M, et al. A novel and

efficient model of coronary artery ligation and myocardial infarction in the mouse.

Circ Res [Internet]. 2010 [cited 2014 Feb 21]. 107(12):1445-53. Available from:


29. Patten RD, Hall-Porter MR. Small animal models of heart failure–Developmet of

novel therapies, past, and present. Circ Heart Fail [Internet]. 2009 [cited 2014 Mar

17]; 2:138-44. Available from:

http://circheartfailure.ahajournals.org/content/2/2/138.full

54 !

! !

54

30. Gaspard GJ, Pasumarthi KB. Quantification of cardiac fibrosis by colour-

subtractive computer-assisted image analysis. Clin Exp Pharmacol Physiol

[Internet]. 2008 [cited 2014 Feb 21]. 35:679-86. Available from:


31. Zhang GX, Ohmori K, Nagai Y, Fujisawa Y, Nishiyama A, Abe Y, Kimura S.

Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative

stress in mice. J Mol Cell Cardiol [Internet]. 2007 [cited 2014 Feb 21]. 42(4):804-

11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17350036

32. Engle SK, Jordan WH, Pritt ML, Chiang AY, Davis MA, Zimmermann JL, et al.

Qualification of cardiac troponin I concentration in mouse serum using

isoproterenol and implementation in pharmacology studies to accelerate drug

development. Toxicol Pathol [Internet]. 2009 [cited 2014 May 21]; 37:617-28.


33. De S, Adhikari S, Devasagayam TPA. Cardioprotective effects of an

aminothiazole compound on isoproterenol-induced myocardial injury in mice.

Cell Biochem Biophys [Internet]. 2013 [cited 2014 May 21]; 67(2):287-95.


34. Rona G. Cathecolamine cardiotoxicity. J Mol Cell Cardiol [Internet]. 1985 [cited

2014 Feb 21]; 17(4):291-306. Available from:


35. Upaganlawar A, Gandhi H, Balaraman R. Isoproterenol induced myocardial

infarction: protective role of natural products. J Pharmacol Toxicol [Internet].

2011 [cited 2014 Feb 21]. 6:1-17. Available from:

http://scialert.net/abstract/?doi=jpt.2011.1.17

36. Soraya H, Khorrami A, Garjani A, Malek-Dizaji N, Garjani A. Acute treatment

with metformin improves cardiac function following isoproterenol-induced

myocardial infarction in rats. Pharmacol Rep [Internet]. 2012 [cited 2014 Feb 21];


37. Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic

dysfunction in mice: structural and functional correlates. Comp Med [Internet].

55 !

! !

55

2009 [cited 2014 Feb 21]; 59(4):339-43. Available:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779208/

38. Wang Y, Wisloff U, Kemi OJ. Animals models in the study of exercise-induced

cardiac hypertrophy. Physiol Res [Internet]. 2010 [cited 2014 Feb 8]; 59(5):633-

44. Available from: http://www.biomed.cas.cz/physiolres/pdf/prepress/931928.pdf

39. Labuzek K, Liber S, Gabryel B, Okopien B. Metformin has adenosine-

monophosphate activated protein kinase (AMPK)-independent effects on LPS-

stimulated rat primary microglial cultures. Pharmacol Rep [Internet]. 2010 [cited

2014 Feb 23]; 62(5):827-48. Available from:


40. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular

and molecular mechanisms of metformin: an overview. Clin Sci (Lond) [Internet].

2012 [cited 2014 Feb 23]; 122(6):253-70. Available from:


41. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular

energy. Nat Rev Mol Cell Biol [Internet]. 2007 [cited 2014 Feb 23]; 8(10):774-85.


42. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol

Toxicol [Internet]. 2007 [cited 2014 Feb 23]; 47:185-210. Available from:


43. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, et al.

Phosphorylation and activation of heart PFK-2 by AMPK has a role in the

stimulation of glycolysis during ischemia. Curr Biol [Internet]. 2000 [cited 2014

Feb 23]; 10(20):1247-55. Available from:


44. Hue L, Rider MH. The AMP-activated protein kinase: more than an energy

sensor. Essays Biochem [Internet]. 2007 [cited 2014 Feb 23]; 43:121-137.


45. Hou X, Song J, Li XN, Zhang L, Wang X, Chen L, et al. Metformin reduces

intracellular reactive oxygen species levels by upregulating expression of the

antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res

56 !

! !

56

Commun [Internet]. 2010 [cited 2014 Feb 23]; 396:199-205. Available from:


46. Bertrand L, Horman S, Beauloye C, Vanocershelde JL. Insulin signalling in the

heart. Cardiovasc Res [Internet]. 2008 [cited 2014 Feb 23]; 79:238-48. Available


47. Proud CG. Signalling to translation: how signal transduction pathways control the

protein synthetic machinery. Biochem J [Internet]. 2007 [cited 2014 Feb 23];

403:217-34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17376031

48. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, et al.

Activation of AMP-activated protein kinase leads to the phosphorylation of

elongation factor 2 and an inhibition of protein synthesis. Curr Biol [Internet].

2002 [cited 2014 Feb 23]; 12:1419-23. Available from:


49. Lee HH, Yeh CH, Chen YT, Chi TC, Cheng JT, Lo SH. Effects of metformin on

rosiglitazone-induced cardiac hypertrophy in mice. Biol Pharm Bull [Internet].

2010 [cited 2014 Feb 23]; 33(9):1506-10. Available from:


50. Charan J, Kantharia ND. How to calculate sample size in animal studies? J

Pharmacol Pharmacother [Internet]. 2013 [cited 2014 Feb 7]; 4(4):303-6.

Available from:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826013/#!po=43.7500

51. National Research Council of the National Academies. Guide for the care and use

of laboratory animals. 8th ed [Internet]. Washington, D.C.: The National

Academies Press; 2011 [cited 2014 Feb 7]. Available from:

http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-laboratory-

animals.pdf

52. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse

gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo

experiments. J Pharm Pharmacol [Internet]. 2008 [cited 2014 Mar 17]; 60(1):63-

70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18088506

57 !

! !

57

53. Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Ablation of both organic

cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has

no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos

[Internet]. 2012 [cited 2014 Mar 17]; 40(6):1170-7. Available from:


54. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Furlong TJ, et al. Clinical

pharmacokinetics of metformin. Clin Pharmacokinet [Internet]. 2011 [cited 2014

Mar 17]; 50(2):81-98. Available from:


55. Khatua TN, Padiya R, Karnewar S, Kuncha M, Agawane SB, Kotamraju, et al.

Garlic provides protection to mice heart against isoproterenol-induced oxidative

damage: role of nitric oxide. Nitric Oxide [Internet]. 2012 [cited 2014 Feb 5];


56. Gupta P, Kanwal A, Putcha UK, Bulani Y, Sojitra B, Khatua TN, et al.

Cardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced

myocardial necrosis: a new therapeutic implication. Jornal of Translational

Medicine [Internet]. 2013 [cited 2014 Feb 8]; 11:80. Available from:

http://www.translational-medicine.com/content/pdf/1479-5876-11-80.pdf

57. Murugesan M, Revathi R, Manju V. Cardioprotective effect of fenugreek on

isoproterenol-induced myocardial infarction in rats. Indian J Pharmacol [Internet].

2011 [cited 2014 Feb 8]; 43:516-9. Available from: http://www.ijp-

online.com/article.asp?issn=0253-

7613;year=2011;volume=43;issue=5;spage=516;epage=519;aulast=Murugesan

58. AVMA Guidelines for the euthanasia of an animals: 2013 edition [Internet].

Schaumburg: American Veterinary Medical Association; 2013 [cited 2014 Feb 7].

Available from: https://www.avma.org/kb/policies/documents/euthanasia.pdf

59. Heart dissection [Internet]. Oxford (UK): European Mouse Phenotyping Resource

of Standardised Screens (EMPReSS); 2004 [cited 2014 Feb 8]. Available from:

http://www.mousebook.org/sops/020_001_heart_dissection_080407.pdf

58 !

! !

58

60. Mouse Morphometry [Internet]. Animal Models of Diabetic Complications

Consortium (AMDCC); 2004 [cited 2014 Feb 8]. Available from:

https://www.diacomp.org/shared/showFile.aspx?doctypeid=3&docid=47

61. Collagen–Masson’s Trichrome stain (TRI) [Internet]. Georgia (USA): The

Internet Pathology Laboratory for Medical Education; date unknown [cited 2014

Feb 8]. Available from:

http://library.med.utah.edu/WebPath/HISTHTML/MANUALS/MASSONS.PDF

62. Helms SA, Azhar G, Zuo C, Theus SA, Bartke A, Wei JY. Smaller cardiac cell

size and reduced extra-cellular collagen might be beneficial for hearts of Ames

dwarf mice. Int J Biol Sci [Internet]. 2010 [cited 2014 Feb 8]; 6(5):475-90.

Available from:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935670/?report=classic

63. Teori sederhana prosedur pemilihan uji hipotesis. In: Dahlan MS. Statistik untuk

kedokteran dan kesehatan. Jakarta (Indonesia): Salemba Medika; 2011. p. 1-29.

64. Statistik deskriptif. In: Dahlan MS. Statistik untuk kedokteran dan kesehatan.

Jakarta (Indonesia): Salemba Medika; 2011. p. 31-60.

65. Uji hipotesis komparatif variabel numerik lebih dari dua kelompok. In: Dahlan

MS. Statistik untuk kedokteran dan kesehatan. Jakarta (Indonesia): Salemba

Medika; 2011. p. 87-128.

66. Analisis kesintasan (Survival analysis). In: Sastroasmoro S, Ismael S. Dasar-dasar

metodologi penelitian klinis. Jakarta (Indonesia): Sagung Seto; 2011. p.245-63.

67. Hoggatt A, Hoggatt J, Honerlaw M, Pelus LM. A spoonful of sugar helps the

medicine go down: a novel technique to improve oral gavage in mice. J Am Assoc

Lab Anim Sci [Internet]. 2010 [cited 2014 Jul 14]; 49(3):329-34Available from:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877306/?report=classic

68. Wu JC, Nasseri BA, Bloch KD, Picard MH, Scherrer-Crosbie M. Influence of sex

on ventricular remodeling after myocardial infarction in mice. J Am Soc

Echocardiogr [Internet]. 2003 [cited 2014 Jul 14]; 16(11):1158-62. Available


69. Van Loo PLP, Van Zutphen LFM, Baumans V. Male management: coping with

aggression problems in male laboratory mice. Lab Anim [Internet]. 2003 [cited

59 !

! !

59

2014 Jul 14]; 37:300-13. Available from:


70. Kaliste-Korhonen E, Eskola S. Fighting in NIH/S male mice: consequence for

behaviour in resident-intruder tests and physiological parameters. Lab Anim

[Internet]. 2000 [cited 2014 Jul 14]; 34:189-98. Available from:

http://lan.sagepub.com/content/34/2/189.full.pdf

60 !

!

LAMPIRAN

Lampiran 1. Ethical Clearance

61 !

!

Lampiran 2. Izin Penelitian

62 !

!

Lampiran 3. Sertifikat Hewan Coba

63 !

!

Lampiran 4. Dokumentasi Penelitian

tempat pemeliharaan hewan coba

penyondean pemberian makan dan minum ad libitum

pengukuran panjang tibia pembedahan

64 !

!

Lampiran 5. Luaran Analisis Program Statistik

Descriptives Luas Penampang Kardiomiosit

N Mean Std.

Deviation Std. Error 95% Confidence Interval for Mean

Minimum Maximum Lower Bound Upper Bound ISO 9 236.18764 63.449817 21.149939 187.41479 284.95849 115.925 330.790 MET+ISO 11 166.65958 39.299550 11.849260 140.25778 193.06137 99.949 234.393 MET 11 156.25721 44.672729 13.469335 126.24566 186.26876 103.179 233.819 K 11 141.87973 23.092445 6.962634 126.36601 157.39344 105.358 183.130 Total 42 172.34384 54.779943 8.452729 155.27321 189.41448 99.949 330.790

Tests of Normality

Group

Kolmogorov-Smirnova Shapiro-Wilk Statistic df Sig. Statistic df Sig. Luas Penampang Kardiomiosit

ISO .199 9 .200* .966 9 .859 MET+ISO .145 11 .200* .981 11 .971 MET .197 11 .200* .915 11 .279 K .171 11 .200* .957 11 .735

*. This is a lower bound of the true significance. a. Lilliefors Significance Correction

65 !

! !

65

Test of Homogeneity of Variances Luas Penampang Kardiomiosit

Levene Statistic df1 df2 Sig. 2.026 3 38 .127

ANOVA

Luas Penampang Kardiomiosit

Sum of Squares df Mean Square F Sig. Between Groups 50093.808 3 16697.936 8.699 .000 Within Groups 72940.719 38 1919.493 Total 123034.526 41

BERAT BADAN HARI KE-1

Descriptives Berat Badan (pre)

N Mean Std.


Minimum Maximum Lower Bound Upper Bound ISO 11 27.18 1.537 .464 26.15 28.21 25 30 MET+ISO 11 27.91 2.982 .899 25.91 29.91 23 32 MET 11 28.82 2.359 .711 27.23 30.40 25 34 K 11 27.36 1.859 .560 26.11 28.61 25 31 Total 44 27.82 2.265 .341 27.13 28.51 23 34

66 !

! !

66

Tests of Normality

Group Kolmogorov-Smirnova Shapiro-Wilk

Statistic df Sig. Statistic df Sig. Berat Badan (pre)

ISO .234 11 .096 .924 11 .351 MET+ISO .123 11 .200* .953 11 .679 MET .197 11 .200* .947 11 .602 K .184 11 .200* .900 11 .187


Test of Homogeneity of Variances Berat Badan (pre)


ANOVA

Berat Badan (pre)


67 !

!

Multiple Comparisons Dependent Variable: Luas Penampang Kardiomiosit

LSD

(I) Group (J) Group Mean

Difference (I-J) Std. Error Sig. 95% Confidence Interval

Lower Bound Upper Bound ISO MET+ISO 69.527065* 19.692036 .001 29.66262 109.39151

MET 79.929429* 19.692036 .000 40.06499 119.79387 K 94.306914* 19.692036 .000 54.44247 134.17136

MET+ISO ISO -69.527065* 19.692036 .001 -109.39151 -29.66262 MET 10.402363 18.681506 .581 -27.41637 48.22109 K 24.779848 18.681506 .193 -13.03888 62.59858

MET ISO -79.929429* 19.692036 .000 -119.79387 -40.06499 MET+ISO -10.402363 18.681506 .581 -48.22109 27.41637 K 14.377485 18.681506 .446 -23.44125 52.19622

K ISO -94.306914* 19.692036 .000 -134.17136 -54.44247 MET+ISO -24.779848 18.681506 .193 -62.59858 13.03888 MET -14.377485 18.681506 .446 -52.19622 23.44125

*. The mean difference is significant at the 0.05 level.

68 !

!

Case Processing Summary: Survival

Group Total N N of Events Censored

N Percent K 11 0 11 100.0%

ISO 11 2 9 81.8% MET 11 0 11 100.0%

MET+ISO 11 0 11 100.0% Overall 44 2 42 95.5%

Overall Comparisons

Chi-Square df Sig. Log Rank (Mantel-Cox) 6.292 3 .098 Breslow (Generalized Wilcoxon) 6.286 3 .099 Tarone-Ware 6.289 3 .098 Test of equality of survival distributions for the different levels of Group.

69 !

!

BERAT BADAN HARI KE-28 Descriptives

Group Statistic Std. Error Berat Badan (post) ISO Mean 26.56 .766

95% Confidence Interval for Mean Lower Bound 24.79 Upper Bound 28.32

5% Trimmed Mean 26.51 Median 27.00 Variance 5.278 Std. Deviation 2.297 Minimum 23 Maximum 31 Range 8 Interquartile Range 3 Skewness .386 .717 Kurtosis 1.172 1.400

MET+ISO Mean 28.27 .935 95% Confidence Interval for Mean Lower Bound 26.19

Upper Bound 30.36 5% Trimmed Mean 28.03 Median 27.00 Variance 9.618 Std. Deviation 3.101 Minimum 25 Maximum 36 Range 11 Interquartile Range 4 Skewness 1.729 .661 Kurtosis 3.375 1.279

MET Mean 26.18 1.016 95% Confidence Interval for Mean Lower Bound 23.92

Upper Bound 28.45 5% Trimmed Mean 26.15 Median 26.00 Variance 11.364 Std. Deviation 3.371 Minimum 22 Maximum 31 Range 9 Interquartile Range 7 Skewness -.096 .661 Kurtosis -1.706 1.279

K Mean 26.09 .780 95% Confidence Interval for Mean Lower Bound 24.35

Upper Bound 27.83 5% Trimmed Mean 26.10 Median 26.00 Variance 6.691 Std. Deviation 2.587 Minimum 22 Maximum 30 Range 8 Interquartile Range 5 Skewness .387 .661 Kurtosis -.646 1.279

70 !

!

Tests of Normality


Statistic df Sig. Statistic df Sig. Berat Badan (post) ISO .201 9 .200* .940 9 .581

MET+ISO .262 11 .033 .830 11 .023 MET .253 11 .048 .869 11 .076 K .241 11 .073 .912 11 .259

Tests of Normality


Statistic df Sig. Statistic df Sig. Transformasi data BB (post) dengan fungsi LG10

ISO .196 9 .200* .946 9 .643 MET+ISO .245 11 .063 .865 11 .067 MET .255 11 .045 .864 11 .065 K .224 11 .131 .924 11 .349


71 !

! !

71

Test of Homogeneity of Variances BB (post) yang ditransformasi


ANOVA

BB (post) yang ditransformasi

Sum of Squares df Mean Square F Sig. Between Groups .009 3 .003 1.375 .265 Within Groups .081 38 .002

Total .090 41

72 !

!

Descriptives

Berat Jantung (BJ)

N Mean Std.


Minimum Maximum Lower Bound Upper Bound ISO 9 136.67 20.616 6.872 120.82 152.51 110 170 MET+ISO 11 129.09 23.856 7.193 113.06 145.12 100 170 MET 11 118.18 18.878 5.692 105.50 130.86 80 150 K 11 130.00 24.495 7.385 113.54 146.46 100 190 Total 42 128.10 22.332 3.446 121.14 135.05 80 190

Tests of Normality


Statistic df Sig. Statistic Df Sig. Berat Jantung (BJ) ISO .186 9 .200* .927 9 .453

MET+ISO .212 11 .180 .894 11 .155 MET .189 11 .200* .958 11 .741 K .251 11 .052 .858 11 .054


73 !

! !

73

Test of Homogeneity of Variances Berat Jantung (BJ)

Levene Statistic df1 df2 Sig. .187 3 38 .905

ANOVA Berat Jantung (BJ)


Descriptives BJ /PT

N Mean Std.


Minimum Maximum Lower Bound Upper Bound ISO 9 6.3489 1.00026 .33342 5.5800 7.1178 4.94 7.87 MET+ISO 11 5.8136 1.08955 .32851 5.0817 6.5456 4.45 7.72 MET 11 5.2864 .73816 .22256 4.7905 5.7823 3.80 6.43 K 11 5.9555 1.10354 .33273 5.2141 6.6968 4.73 8.67 Total 42 5.8274 1.02829 .15867 5.5069 6.1478 3.80 8.67

74 !

! !

74

Tests of Normality


Statistic df Sig. Statistic df Sig. BJ /PT ISO .171 9 .200* .947 9 .660

MET+ISO .200 11 .200* .895 11 .160 MET .119 11 .200* .974 11 .928 K .179 11 .200* .870 11 .078


Test of Homogeneity of Variances BJ /PT

Levene Statistic df1 df2 Sig. .453 3 38 .717

75 !

!

ANOVA BJ /PT

Sum of Squares df Mean Square F Sig. Between Groups 5.850 3 1.950 1.976 .134 Within Groups 37.502 38 .987 Total 43.352 41

Descriptives BJ/BB

N Mean Std.


Minimum Maximum Lower Bound Upper Bound ISO 9 5.2000 .97848 .32616 4.4479 5.9521 3.55 6.52 MET+ISO 11 4.5645 .68238 .20575 4.1061 5.0230 3.70 6.07 MET 11 4.5518 .79004 .23820 4.0211 5.0826 3.64 5.91 K 11 5.0018 .93065 .28060 4.3766 5.6270 4.00 7.31 Total 42 4.8119 .86091 .13284 4.5436 5.0802 3.55 7.31

76 !

!

Tests of Normality


Statistic df Sig. Statistic df Sig. BJ/BB ISO .197 9 .200* .939 9 .566

MET+ISO .178 11 .200* .934 11 .448 MET .204 11 .200* .896 11 .164 K .185 11 .200* .860 11 .058


Test of Homogeneity of Variances BJ/BB

Levene Statistic df1 df2 Sig.

.348 3 38 .791

ANOVA BJ/BB

Sum of Squares df Mean Square F Sig. Between Groups 3.169 3 1.056 1.475 .237 Within Groups 27.219 38 .716

Total 30.388 41

77 !

!

Lampiran 6. Biodata Mahasiswa

Identitas

Nama : Ihsan Fadilah

NIM : 22010110120066

TTL : Kotabumi, 18 Oktober 1992

Jenis Kelamin : Laki-laki

Alamat : Jalan Citra H30 Graha Estetika, Banyumanik, Semarang

Nomor Telp. : (024) 7463577

Nomor Ponsel : +6285279343000

E-mail : [email protected]

Riwayat Pendidikan Formal

1. TK : TK Tunas Harapan, Lampung Utara Lulus tahun : 1998

2. SD : SDN 4 Tanjungaman, Lampung Utara Lulus tahun : 2004

3. SMP : SMPN 7 Kotabumi, Lampung Utara Lulus tahun : 2007

4. SMA : SMAN 2 Bandarlampung Lulus tahun : 2010

5. FK Undip, masuk tahun : 2010

Keanggotaan Organisasi

1. Kelompok Studi Mahasiswa FK Undip Tahun 2010 s.d 2014

2. Asisten Mahasiswa Bagian Anatomi FK Undip Tahun 2012 s.d 2014

3. Pengabdian Masyarakat BEM FK Undip Tahun 2011 s.d 2013

4. Asisten Mahasiswa Bagian Kimia FK Undip Tahun 2011 s.d 2012

5. Rohis SMAN 2 Bandarlampung Tahun 2007 s.d 2010

6. Karya Ilmiah Remaja SMAN 2 Bandarlampung Tahun 2007 s.d 2009

7. Kesenian OSIS SMPN Kotabumi Tahun 2005 s.d 2006

Pengalaman Penelitian

1. Yoghurt Kacang Tanah (Arachis hypogaea) sebagai Inovasi Pangan Sehat

Anti-osteoporosis: Sebuah Studi Eksperimental pada Tikus Wistar Model

Osteoporosis, 2014.

78 !

! !

78

2. Prevalensi Infeksi Cacing Cambuk (Trichuris trichiura) dan Cacing Tambang

(Necator americanus dan Ancylostoma duodenale) pada Ibu Hamil di Kota

Semarang, 2013-2014.

3. Analisis Genotype-Phenotype pada Penderita dan Karier Penderita Leber

Hereditary Optic Neuropathy di Indonesia, 2012.

4. Efek Pemberian Yoghurt Kacang Tanah (Phaseolus vulgaris) terhadap Profil

Lipid Serum dan Jumlah Coliform serta Lactobacilli Feses pada Tikus

Dislipidemia, 2011.

Pengalaman Presentasi dan Mengikuti Lomba Karya Ilmiah



Osteoporosis. Direktorat Penelitian dan Pengabdian kepada Masyarakat

Ditjen Pendidikan Tinggi Kementerian Pendidikan Nasional. [Penelitian

Didanai]

2. Potensi Gen Antibodi PreS2 dalam Vektor Adenovirus melalui Microneedle

Patch sebagai Vaccinotherapy Hepatitis B dan Karsinoma Hepatoseluler.

FKK Universitas Muhammadiyah Jakarta. [Juara 1 Poster Ilmiah - Nasional]

3. Efek Pemberian Metformin terhadap Hipertrofi Miosit dan FIbrosis

Interstisial Jantung pada Mencit Pasca-Infark Miokardium yang Diinduksi

dengan Isoproterenol. Bidang Riset Himpunan Mahasiswa Kedokteran

Umum Undip. [Juara 3 Proposal Penelitian - Program Studi]

4. Mycospray Berbasis Aspergillus niger Entomopatogenik: Sebuah Inovasi

Pengontrolan Resistensi dan Populasi Aedes aegypti dalam Upaya

Pengendalian Dengue. Departemen Riset BEM FK KM Undip. [Juara 1

Proposal Penelitian - Fakultas]



Osteoporosis. Departemen Riset BEM FK KM Undip. [Juara 2 Proposal

Penelitian - Fakultas]

79 !

! !

79

6. Evidence-Based Medicine: Tribendimidine sebagai Obat Alternatif Terbaru

untuk Terapi Ascariasis. Badan Analisis dan Pengembangan Ilmiah Nasional

(BAPIN)-Ikatan Senat Mahasiswa Kedokteran Indonesia (ISMKI) beserta FK

Universitas Padjajaran. [Finalis 6 Besar Gagasan Tertulis - Nasional]

7. Mycospray Berbasis Aspergillus niger Entomopatogenik: Sebuah Inovasi

Pengontrolan Resistensi dan Populasi Aedes aegypti dalam Upaya

Pengendalian Dengue. Himpunan Mahasiswa Kedokteran Umum Undip.

[Juara 1 Gagasan Tertulis - Nasional]

8. Potensi Gen Antibodi PreS2 dalam Vektor Adenovirus melalui Microneedle

Patch sebagai Vaccinotherapy Hepatitis B dan Karsinoma Hepatoseluler.

Himpunan Mahasiswa Kedokteran Umum Undip. [Juara 3 Gagasan Tertulis-

Nasional]

9. Curcumin in Curcuma longa as Inflammoregulator to Prevent

Carcinogenesis of Colitis-associated Colorectal Cancer Promoted by

Commensal pks+ Escherichia coli. FK Universitas Indonesia. [Juara ke-5

Literature Review - Internasional]

10. Efek Pemberian Yoghurt Kacang Merah (Phaseolus vulgaris) terhadap Profil


Dislipidemia. FK Udayana. [Juara 3 Penelitian - Nasional]

11. Potensi Antibodi PreS2 dalam Vektor Adenovirus melalui Microneedle Patch

sebagai Vaccinotherapy Hepatitis B dan Karsinoma Hepatoseluler. FK

Udayana. [Finalis 10 Besar Poster Ilmiah - Nasional]

12. Efek Pemberian Yoghurt Kacang Tanah (Arachis hypogaea) terhadap Kadar

C-Telopeptida Serum, Kadar Alkali Fosfatase Serum dan Gambaran

Histopatologi Tulang pada Tikus Ovariektomi Model Osteoporosis. Bidang

Riset Himpunan Mahasiswa Kedokteran Umum Undip. [Juara 1 Proposal

Penelitian - Program Studi]

13. Potensi Idebenone untuk Optimalisasi Fungsi Mitokondria pada Penderita

Leber Hereditary Optic Neuropathy (LHON). FK Universitas Sriwijaya.

[Finalis 10 Besar Gagasan Tertulis - Nasional]

80 !

! !

80

14. Analisis Genotype-Phenotype pada Penderita dan Karier Leber Hereditary

Optic Neuropathy di Indonesia. FK Undip. [Penelitian didanai]



Dislipidemia. Direktorat Penelitian dan Pengabdian kepada Masyarakat

Ditjen Pendidikan Tinggi Kementerian Pendidikan Nasional. [Penelitian

Didanai]



Dislipidemia. Fakultas Teknik Undip. [Juara 1 Proposal Penelitian -

Universitas]

Documents

Ihsan Fadilah_22010110120066_Bab8KTI